Literature DB >> 30222160

A High-Throughput Luciferase Assay to Evaluate Proteolysis of the Single-Turnover Protease PCSK9.

John S Chorba1, Adri M Galvan2, Kevan M Shokat2.   

Abstract

Proprotein convertase subtilisin/kexin type 9 (PCSK9) is a single-turnover protease which regulates serum low-density lipoprotein (LDL) levels and, consequently, cardiovascular disease. Although PCSK9 proteolysis is required for its full hypercholesterolemic effect, the evaluation of its proteolytic function is challenging: PCSK9 is only known to cleave itself, undergoes only a single turnover, and after proteolysis, retains its substrate in its active site as an auto-inhibitor. The methods presented here describe an assay which overcomes these challenges. The assay focuses on intermolecular proteolysis in a cell-based context and links successful cleavage to the secreted luciferase activity, which can be easily read out in the conditioned medium. Via sequential steps of mutagenesis, transient transfection, and a luciferase readout, the assay can probe PCSK9 proteolysis under conditions of either genetic or molecular perturbation in a high-throughput manner. This system is well suited for both the biochemical evaluation of clinically discovered missense single-nucleotide polymorphisms (SNPs), as well as for the screening of small-molecule inhibitors of PCSK9 proteolysis.

Entities:  

Mesh:

Substances:

Year:  2018        PMID: 30222160      PMCID: PMC6231911          DOI: 10.3791/58265

Source DB:  PubMed          Journal:  J Vis Exp        ISSN: 1940-087X            Impact factor:   1.355


  18 in total

1.  A Simple Statistical Parameter for Use in Evaluation and Validation of High Throughput Screening Assays.

Authors: 
Journal:  J Biomol Screen       Date:  1999

2.  The proprotein convertase (PC) PCSK9 is inactivated by furin and/or PC5/6A: functional consequences of natural mutations and post-translational modifications.

Authors:  Suzanne Benjannet; David Rhainds; Josée Hamelin; Nasha Nassoury; Nabil G Seidah
Journal:  J Biol Chem       Date:  2006-08-15       Impact factor: 5.157

3.  Stepwise processing analyses of the single-turnover PCSK9 protease reveal its substrate sequence specificity and link clinical genotype to lipid phenotype.

Authors:  John S Chorba; Adri M Galvan; Kevan M Shokat
Journal:  J Biol Chem       Date:  2017-12-19       Impact factor: 5.157

4.  Cost-effectiveness of PCSK9 Inhibitor Therapy in Patients With Heterozygous Familial Hypercholesterolemia or Atherosclerotic Cardiovascular Disease.

Authors:  Dhruv S Kazi; Andrew E Moran; Pamela G Coxson; Joanne Penko; Daniel A Ollendorf; Steven D Pearson; Jeffrey A Tice; David Guzman; Kirsten Bibbins-Domingo
Journal:  JAMA       Date:  2016-08-16       Impact factor: 56.272

5.  Cardiovascular Efficacy and Safety of Bococizumab in High-Risk Patients.

Authors:  Paul M Ridker; James Revkin; Pierre Amarenco; Robert Brunell; Madelyn Curto; Fernando Civeira; Marcus Flather; Robert J Glynn; Jean Gregoire; J Wouter Jukema; Yuri Karpov; John J P Kastelein; Wolfgang Koenig; Alberto Lorenzatti; Pravin Manga; Urszula Masiukiewicz; Michael Miller; Arend Mosterd; Jan Murin; Jose C Nicolau; Steven Nissen; Piotr Ponikowski; Raul D Santos; Pamela F Schwartz; Handrean Soran; Harvey White; R Scott Wright; Michal Vrablik; Carla Yunis; Charles L Shear; Jean-Claude Tardif
Journal:  N Engl J Med       Date:  2017-03-17       Impact factor: 91.245

6.  Post-transcriptional regulation of low density lipoprotein receptor protein by proprotein convertase subtilisin/kexin type 9a in mouse liver.

Authors:  Sahng Wook Park; Young-Ah Moon; Jay D Horton
Journal:  J Biol Chem       Date:  2004-09-22       Impact factor: 5.157

7.  Adenoviral-mediated expression of Pcsk9 in mice results in a low-density lipoprotein receptor knockout phenotype.

Authors:  Kara N Maxwell; Jan L Breslow
Journal:  Proc Natl Acad Sci U S A       Date:  2004-04-26       Impact factor: 11.205

8.  NARC-1/PCSK9 and its natural mutants: zymogen cleavage and effects on the low density lipoprotein (LDL) receptor and LDL cholesterol.

Authors:  Suzanne Benjannet; David Rhainds; Rachid Essalmani; Janice Mayne; Louise Wickham; Weijun Jin; Marie-Claude Asselin; Josée Hamelin; Mathilde Varret; Delphine Allard; Mélanie Trillard; Marianne Abifadel; Angie Tebon; Alan D Attie; Daniel J Rader; Catherine Boileau; Louise Brissette; Michel Chrétien; Annik Prat; Nabil G Seidah
Journal:  J Biol Chem       Date:  2004-09-09       Impact factor: 5.157

9.  The proprotein convertase subtilisin/kexin type 9 (PCSK9) active site and cleavage sequence differentially regulate protein secretion from proteolysis.

Authors:  John S Chorba; Kevan M Shokat
Journal:  J Biol Chem       Date:  2014-09-10       Impact factor: 5.157

10.  Catalytic activity is not required for secreted PCSK9 to reduce low density lipoprotein receptors in HepG2 cells.

Authors:  Markey C McNutt; Thomas A Lagace; Jay D Horton
Journal:  J Biol Chem       Date:  2007-05-29       Impact factor: 5.157

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.